Ocriplasmin for Treating Vitreomacular Traction (TA297)

Technology Appraisal Guidance No. 297

Source: National Institute for Health and Care Excellence

 1. Guidance

1.1 Ocriplasmin is recommended as an option for treating vitreomacular traction in adults, only if:

  • an epiretinal membrane is not present


  • they have a stage II full-thickness macular hole with a diameter of 400 micrometres or less and/or
  • they have severe symptoms.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA297

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Ocriplasmin for treating vitreomacular traction.

Issue Date: October 2013

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more